参考文献/References:
[1] Wang L,Peng W,Zhao Z,et al. Prevalence and treatment of diabetes in China,2013-2018[J]. JAMA,2021,326(24):2498-2506.
[2] Wei J,Zhao Y,Liang H,et al. Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy[J]. Acta Pharm Sin B,2022,12(1):1-17.
[3] 王一硕,罗皓文,王晨旭,等. 线粒体动力学在糖尿病心肌病中的研究进展[J]. 心血管病学进展,2023,44(12):1111-1115.
[4] EL Hayek MS,Ernande L,Benitah JP,et al. The role of hyperglycaemia in the development of diabetic cardiomyopathy[J]. Arch Cardiovasc Dis,2021,114(11):748-760.
[5] Hou CY,Tain YL,Yu HR,et al. The effects of resveratrol in the treatment of metabolic syndrome[J]. Int J Mol Sci,2019,20(3):535.
[6]Song,YJ,Zhong CB,Wu,W,et al. Resveratrol and diabetic cardiomyopathy:focusing on the protective signaling mechanisms[J]. Oxid Med Cell Longev ,2020,2020:7051845.
[7] Jin L ,Geng L ,Ying L,et al. FGF21-sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity[J]. Circulation,2022,146(20):1537-1557.
[8] Westermeier F,Riquelme JA,Pavez M,et al. New Molecular Insights of Insulin in Diabetic Cardiomyopathy[J]. Front Physiol,2016,7:125.
[9]Jia G,DeMarco VG,Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat Rev Endocrinol,2016,12(3):144-153.
[10]Li Z,Shi Y,Xia Y,et al. Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy[J]. J Clin Med,2023,12(4):1565.
[11] Brereton MF,Rohm M,Shimomura K,et al. Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells[J]. Nat Commun,2016,7:13496.
[12]Byrne NJ,Rajasekaran NS,Abel ED,et al. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy[J]. Free Radic Biol Med,2021,169:317-342.
[13]Wang J,Tang Z,Zhang Y,et al. Matrine alleviates AGEs- induced cardiac dysfunctions by attenuating calcium overload via reducing ryanodine receptor 2 activity[J]. Eur J Pharmacol,2019,842:118-124.
[14] Tian CJ,Zhang JH,Liu J,et al. Ryanodine receptor and immune-related molecules in diabetic cardiomyopathy[J]. ESC Heart Fail,2021,8(4):2637-2646.
[15]James DE,St?ckli J,Birnbaum MJ. The aetiology and molecular landscape of insulin resistance[J]. Nat Rev Mol Cell Biol,2021,22(11):751-771.
[16] Peng C,Zhang Y,Lang X,et al. Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy:new insights from bioinformatics analysis[J]. J Transl Med,2023,21(1):66.
[17] Galiniak S,Aebisher D,Bartusik-Aebisher D. Health benefits of resveratrol administration[J]. Acta Biochim Pol,2019,66(1):13-21.
[18]Lu C,Xing H,Yang L,et al. Resveratrol ameliorates high-fat-diet-induced abnormalities in hepatic glucose metabolism in mice via the AMP-activated protein kinase pathway[J]. Evid Based Complement Alternat Med,2021,2021:6616906.
[19] Vlavcheski F ,Den Hartogh DJ,Giacca A,et al. Amelioration of high-insulin-induced skeletal muscle cell insulin resistance by resveratrol is linked to activation of AMPK and restoration of GLUT4 translocation[J]. Nutrients,2020,12(4):914.
[20] González-Rodríguez ?,Santamaría B,Mas-Gutierrez JA,et al. Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner[J]. Mol Nutr Food Res,2015,59(8):1431-1442.
[21]Zeraattalab-Motlagh S,Jayedi A,Shab-Bidar S. The effects of resveratrol supplementation in patients with type 2 diabetes,metabolic syndrome,and nonalcoholic fatty liver disease:an umbrella review of meta-analyses of randomized controlled trials[J]. Am J Clin Nutr,2021,114(5):1675-1685.
[22]Springer M,Moco S. Resveratrol and its human metabolites-effects on metabolic health and obesity[J]. Nutrients,2019,11(1):143.
[23]Sun H,Liu X,Long SR,et al. Antidiabetic effects of pterostilbene through PI3K/Akt signal pathway in high fat diet and STZ-induced diabetic rats[J]. Eur J Pharmacol,2019,859:172526.
[24] Ardid-Ruiz A,Ibars M,Mena P,et al. Potential involvement of peripheral leptin/STAT3 signaling in the effects of resveratrol and its metabolites on reducing body fat accumulation[J]. Nutrients,2018,10(11):1757.
[25] Peng ML,Fu Y,Wu CW,et al. Signaling pathways related to oxidative stress in diabetic cardiomyopathy[J]. Front Endocrinol (Lausanne),2022,13:907757.
[26] Guo S,Yao Q,Ke Z,et al. Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK[J]. Mol Cell Endocrinol,2015,412:85-94.
[27] Bagul PK,Deepthi N,Sultana,et al. Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3[J]. J Nutr Biochem,2015,26(11):1298-1307.
[28] Wang G,Song X,Zhao L,et al. Resveratrol prevents diabetic cardiomyopathy by increasing Nrf2 expression and transcriptional activity[J]. Biomed Res Int,2018,2018:2150218.
[29] Wu H,Li GN,Xie J,et al. Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in STZ-induced diabetic mice[J]. BMC Cardiovasc Disord,2016,16:5.
[30]Lontchi-Yimagou E,Sobngwi E,Matsha TE,et al. Diabetes mellitus and inflammation[J]. Curr Diab Rep,2013,13(3):435-444.
[31] Wu H,Chen Z,Xie J,et al. High mobility group box-1:a missing link between diabetes and its complications[J] Mediators Inflamm ,2016;2016:3896147.
[32] Gao Y,Kang L,Li C,et al. Resveratrol ameliorates diabetes-induced cardiac dysfunction through AT1R-ERK/p38 MAPK signaling pathway[J]. Cardiovasc Toxicol,2016,16(2):130-137.
[33] Luo B,Li B,Wang W,et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model[J]. PLoS One,2014,9(8):e104771.
[34] Li A,Zhang S,Li J,et al. Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice[J]. Mol Cell Endocrinol,2016,434:36-47.
[35]Mahjabeen W,Khan DA,Mirza SA. Role of resveratrol supplementation in regulation of glucose hemostasis,inflammation and oxidative stress in patients with diabetes mellitus type 2:a randomized,placebo-controlled trial[J]. Complement Ther Med,2022,66:102819.
[36] Mialet-Perez J,Vindis C.. Autophagy in health and disease:focus on the cardiovascular system[J]. Essays Biochem,2017,61(6):721-732.
[37] Wang B,Yang Q,Sun YY,et al. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice[J]. J Cell Mol Med,2014,18(8):1599-1611.
[38] Xu K,Liu XF,Ke ZQ,et al. Resveratrol modulates apoptosis and autophagy induced by high glucose and palmitate in cardiac cells[J]. Cell Physiol Biochem,2018,46(5):2031-2040.
相似文献/References:
[1]王静娜,侯瑞田,史亦男,等.糖尿病心肌病发病机制及病理改变研究进展[J].心血管病学进展,2016,(4):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
WANG Jingna,HOU Ruitian,SHI Yinan,et al.Research Progress on Pathogenesis and Pathological Changes
of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(11):412.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.022]
[2]杨沫,姜文锡.线粒体功能异常在糖尿病心肌病发病机制中的作用[J].心血管病学进展,2015,(6):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
YANG Mo,JIANG Wenxi.Mitochondrial Dysfunction of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(11):731.[doi:10.3969/j.issn.1004-3934.2015.06.019]
[3]朱月红,戴启明.糖尿病心肌病的内质网病变机制及干预[J].心血管病学进展,2015,(6):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
ZHU Yuehong,DAI Qiming.Advance of Mechanism and Intervention of Endoplasmic Reticulum in
Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(11):738.[doi:10.3969/j.issn.1004-3934.2015.06.021]
[4]位晨晨,钟明.糖尿病心肌病的发病机制[J].心血管病学进展,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
WEI Chenchen,ZHONG Ming.Pathogenesis of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
[5]武韧 常贵全 孙凤起 李鸿珠.硫化氢对糖尿病心肌病的保护作用[J].心血管病学进展,2021,(1):52.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
WU Ren,CHANG Guiquan,SUN Fengqi,et al.Protective Effect of Hydrogen Sulfide in Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):52.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[6]宋元秀 崔鸣.线粒体动力学异常与相关心血管疾病[J].心血管病学进展,2021,(2):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
SONG Yuanxiu,CUI Ming.Correlation Between Mitochondrial Dynamics and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2021,(11):162.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]马韵之 李剑 周鹏.糖尿病心肌病血清生物标志物研究进展[J].心血管病学进展,2021,(5):392.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.002]
Serum Biomarkers of Diabetic Cardiomyopathy.[J].Advances in Cardiovascular Diseases,2021,(11):392.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.002]
[8]李艳鹏 马依彤.糖尿病心肌病治疗策略的研究进展[J].心血管病学进展,2022,(9):795.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.007]
LI Yanpeng,MA Yitong.Treatment Strategies for Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(11):795.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.007]
[9]曹兴丹 陈子仪 宋小刚 张玉秀 陈敏 汤吉超 李萍萍 陈永清 荆哲.EMRE在高糖环境中的变化对心肌细胞凋亡机制的研究[J].心血管病学进展,2022,(10):953.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.020]
CAO XingdanCHEN ZiyiSONG XiaogangZHANG YuxiuCHEN MinTANG JichaoLI PingpingCHEN YongqingJING Zhe.Effect of High Glucose-Induced EMRE Expressions Changes on?yocardial Apoptosis[J].Advances in Cardiovascular Diseases,2022,(11):953.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.020]
[10]林佳音 王莉莉 于小晴.胰高血糖素样肽-1受体激动剂对糖尿病心肌病的影响[J].心血管病学进展,2023,(11):1024.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.015]
LIN Jiayin,WANG Lili,YU Xiaoqing.Effect of Glucagon-Like Peptide-1 Receptor Agonist on Diabetes Cardiomyopathy[J].Advances in Cardiovascular Diseases,2023,(11):1024.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.015]